



**Food and Drug Administration
OFFICE OF CRIMINAL INVESTIGATIONS
REPORT OF INVESTIGATION**

REPORTING OFFICE: San Francisco Resident Office

DOCUMENT NUMBER: 258349

CASE NUMBER: 2010-SFC-735-0280-J

RELATED CASE NUMBER: (b) (7)(E)

TYPE OF CASE: 735.100, DIETARY SUPPLEMENTS - CDER

CASE TITLE: PRIMORDIAL PERFORMANCE

CASE AGENT: (b) (7)(F)

INVESTIGATION MADE AT: San Jose, CA

INVESTIGATION MADE BY: SA (b) (7)(F)

REPORTING PERIOD: **FROM:** 07/13/2017 **TO:** 09/06/2017

STATUS OF CASE: Continued

SYNOPSIS: Trial preparation; jury trial.

RESTRICTED INFORMATION

This report is furnished on an official need-to-know basis and must be protected from dissemination which might compromise the best interests of the Food and Drug Administration, Office of Criminal Investigations. This report shall not be released in response to a Freedom of Information Act or Privacy Act request or disseminated to other parties without prior consultation with the FDA Office of Criminal Investigations.

UNAUTHORIZED RELEASE MAY RESULT IN CRIMINAL PROSECUTION

REPORT SUBMITTED BY: Electronically submitted by (b) (7)(F) _____ DATE: 09/13/2017
(b) (7)(F) _____, SPECIAL AGENT

REPORT APPROVED BY: Electronically approved by LISA MALINOWSKI _____ DATE: 09/18/2017
LISA MALINOWSKI, SPECIAL AGENT IN CHARGE

DISTRIBUTION: ORIG: SFC

1. INTRODUCTION:

This case originated after the February 8, 2010, receipt of information from the United States Anti-Doping Agency (USADA) about an email solicitation from PRIMORDIAL PERFORMANCE on the sale of a new product called Superdrone. The email indicates that PRIMORDIAL PERFORMANCE's Superdrone is a "Superdrol-clone" and contains the designer anabolic steroid methyldrostanolone. Superdrol (aka methyldrostanolone, aka methasteron) is a designer anabolic steroid (b) (7)(E)

(b) (7)(E)

Reference is made to the Report of Investigation for the period April 13, 2017 through July 12, 2017.

2. DETAILS OF INVESTIGATION:

From July 13, 2017 until the start of the jury trial on August 11, 2017, Special Agent (b) (7)(F) prepared for trial.

3. JUDICIAL ACTION:

On August 11, 2017 the fifth count of the indictment, 21 USC 331(a) - Introduction of a misbranded drug into interstate commerce (misdemeanor) was dismissed. On the same date the jury trial began in the Northern District of California, San Jose, CA.

On August 24, 2017, following a jury trial, ERIC POTRATZ was acquitted on the remaining five counts listed on the indictment.

The Judicial Action Form and Subject History Form for POTRATZ was updated. The Case Initiation was also updated.

4. DISPOSITION OF EVIDENCE, CONTRABAND, AND PERSONAL PROPERTY:

None.

5. STATUS OF INVESTIGATION:

Continued.

6. SUSPECTS/DEFENDANTS/OTHER:

PRIMORDIAL PERFORMANCE
ERIC POTRATZ

(b) (6), (b) (7)(C)

WWW.PRIMORDIALPERFORMANCE.COM

(b) (6), (b) (7)(C)

M

7. ATTACHMENTS:

None.